For more than 15 years, we have been working to fulfill our promise of bringing PROVENGE® (sipuleucel-T) to market in order to transform the lives of patients. Our journey has not been easy. Nothing worth fighting for ever is.
Early on, we said, “not if, but when.” We recognized the power and potential of active cellular immunotherapy (ACI) to fight cancer. Thanks to that pioneering vision and the dedication of the more than 1,000 courageous patients and dedicated physicians who have participated in our clinical trials, PROVENGE is now available.
We recognize that the U.S. Food and Drug Administration (FDA) approval of PROVENGE is a major milestone for our company, but more importantly, for patients.
What makes our work so meaningful is seeing patients benefit. And that is what drives our commitment to furthering this scientific progress and exploring our ACI therapy in cancers beyond prostate.
We're deeply appreciative of the efforts of the clinical investigators, healthcare professionals, patients, and advocates with whom we’ve worked, as well as our own employees and advisors, all of whom share the commitment and passion that have led us here today.
Together, we have changed the way prostate cancer is treated. That is worth fighting for. And for all of us, this is just the beginning.
Mitchell H. Gold, M.D.
President, Chief Executive Officer and Director
Dendreon Corporation
Print page
Email page